Structure Financial Statements From 2010 to 2026

GPCR Stock   62.26  0.51  0.81%   
Structure Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Structure Therapeutics' valuation are provided below:
Market Capitalization
4.8 B
Earnings Share
(3.66)
There are over one hundred nineteen available fundamental trend indicators for Structure Therapeutics American, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check Structure Therapeutics' current fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction.
Check Structure Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Structure Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 374.3 K, Net Interest Income of 43.5 M or Depreciation And Amortization of 1.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.56. Structure financial statements analysis is a perfect complement when working with Structure Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Structure Stock
Check out the analysis of Structure Therapeutics Correlation against competitors.

Structure Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 BB244.1 M
Slightly volatile
Short and Long Term Debt Total2.3 M4.4 M1.2 M
Slightly volatile
Other Current Liabilities31.8 M30.2 M7.7 M
Slightly volatile
Total Current Liabilities43.5 M41.4 M11.8 M
Slightly volatile
Property Plant And Equipment Net4.1 M8.1 MM
Slightly volatile
Accounts Payable5.2 M9.2 M3.1 M
Slightly volatile
Cash98.4 M194.9 M53.2 M
Slightly volatile
Non Current Assets Total14.6 M13.9 M3.5 M
Slightly volatile
Non Currrent Assets Other6.2 M5.9 M1.2 M
Slightly volatile
Other Assets1.091.15215.4 K
Pretty Stable
Cash And Short Term Investments1.1 BB237.9 M
Slightly volatile
Common Stock Shares Outstanding43.8 M60.5 M39.4 M
Slightly volatile
Short Term Investments862.2 M821.1 M178.4 M
Slightly volatile
Liabilities And Stockholders Equity1.1 BB244.1 M
Slightly volatile
Non Current Liabilities Total2.1 M2.2 M59.9 M
Pretty Stable
Capital Lease Obligations4.7 M4.4 M1.1 M
Slightly volatile
Other Current Assets9.3 M8.8 M2.8 M
Slightly volatile
Other Stockholder Equity1.4 B1.4 B274.8 M
Slightly volatile
Total Liabilities32.9 M34.6 M70.4 M
Very volatile
Property Plant And Equipment Gross10.4 M9.9 M2.3 M
Slightly volatile
Total Current Assets1.1 BB240.6 M
Slightly volatile
Capital Stock20.5 K19.6 K4.2 K
Slightly volatile
Net Working CapitalB983.5 M200 M
Slightly volatile
Short Term Debt2.1 MM551 K
Slightly volatile
Common Stock20.5 K19.6 K4.9 K
Slightly volatile
Property Plant Equipment1.2 M1.5 M673 K
Slightly volatile
Deferred Long Term Liabilities4.1 M3.9 M1.1 M
Slightly volatile
Current Deferred Revenue284.8 K320.4 K349.7 K
Slightly volatile
Non Current Liabilities Other330 K347.3 K303 K
Slightly volatile

Structure Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision374.3 K356.5 K76.2 K
Slightly volatile
Depreciation And Amortization1.2 M1.1 M246.8 K
Slightly volatile
Interest Expense16.2 M15.4 M3.5 M
Slightly volatile
Selling General Administrative59.7 M56.8 M13.2 M
Slightly volatile
Other Operating Expenses191.1 M182 M42.6 M
Slightly volatile
Research Development131.4 M125.1 M29.5 M
Slightly volatile
Cost Of Revenue3.1 MM634.3 K
Slightly volatile
Total Operating Expenses191.1 M182 M42.6 M
Slightly volatile
Income Tax Expense374.3 K356.5 K89.8 K
Slightly volatile
Selling And Marketing Expenses0.80.90.9824
Slightly volatile

Structure Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation22.7 M21.6 M4.8 M
Slightly volatile
Change In Working Capital3.9 M3.4 MM
Slightly volatile
Begin Period Cash Flow156.7 M149.3 M51.1 M
Slightly volatile
Depreciation1.2 M1.1 M248.7 K
Slightly volatile
Capital Expenditures1.1 M1.5 M445.6 K
Slightly volatile
Issuance Of Capital Stock621.3 M591.8 M131.3 M
Slightly volatile
Total Cash From Financing Activities622.2 M592.6 M152.8 M
Slightly volatile
End Period Cash Flow98.4 M194.9 M53.2 M
Slightly volatile
Change To Netincome1.6 M2.2 M1.1 M
Slightly volatile
Change To Liabilities1.9 M2.5 M1.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation1.471.170.6976
Slightly volatile
Payables Turnover0.310.290.0852
Slightly volatile
Cash Per Share15.8615.114.0802
Slightly volatile
Days Payables Outstanding1.2 K1.3 K18.8 K
Slightly volatile
Income Quality0.440.860.2381
Slightly volatile
Current Ratio27.0328.458.9 K
Slightly volatile
Capex Per Share0.01410.02210.0073
Slightly volatile
Interest Debt Per Share0.0960.0660.0506
Slightly volatile
Debt To Assets0.00470.00495.0114
Slightly volatile
Days Of Payables Outstanding1.2 K1.3 K18.8 K
Slightly volatile
Ebt Per Ebit1.010.890.965
Slightly volatile
Total Debt To Capitalization0.00490.00510.0725
Pretty Stable
Quick Ratio27.0328.458.9 K
Slightly volatile
Net Income Per E B T1.11.151.0211
Slightly volatile
Cash Ratio6.495.415.6005
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.820.910.9896
Slightly volatile
Debt Ratio0.00470.00495.0114
Slightly volatile

Structure Fundamental Market Drivers

Structure Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Structure Therapeutics Financial Statements

Structure Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Structure Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Structure Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Structure Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue320.4 K284.8 K
Cost Of RevenueM3.1 M

Pair Trading with Structure Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Structure Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Structure Stock

  0.82PG Procter GamblePairCorr
  0.65MSFT Microsoft Sell-off TrendPairCorr
  0.63HPQ HP IncPairCorr
  0.63HD Home DepotPairCorr
The ability to find closely correlated positions to Structure Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Structure Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Structure Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Structure Therapeutics American to buy it.
The correlation of Structure Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Structure Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Structure Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Structure Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Structure Stock Analysis

When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.